Haemin Go / Friday, March 31, 2023 / Categories: ICU & Critical Care, Care Team, Critical Care, Neuro, PT/OT, Stroke Team, Diagnosis, ICH, SAH, Topics, Bleeding, BP Targets, Complic. Prevention, Types of Content, Podcast, Post-ICU Care, Care Team, Case Man., Neuro, Nursing, Pharm, Physiatry, PT/OT, Diagnosis, ICH, SAH, Topics, Anti-coag, BP, Controversies, Types of Content, Podcast, Content Types, Podcast, CE/CME The Role of Real World Evidence in Driving Clinical Care for Anticoagulated Patients with Life-Threatening Bleeding Moderator: W. Brian Gibler, MD, FACEP, FACC, FAHA Other Participants: Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP; Gregory J. Fermann, MD; Natalie Kreitzer, MD, MS In this podcast, experts in Emergency Medicine, Pharmacy, and Neurocritical Care describe important real world data which emphasize the use of specific reversal therapy for patients with life-threatening bleeding in the anticoagulated patient. These large retrospective trials describe patient care in multiple hospitals with large numbers of patients. For patients with Factor Xa-associated bleeding, real world evidence indicates that specific reversal using andexanet alfa is superior to nonspecific repletion therapy. Decreased mortality is associated with this specific reversal therapy. The clinician needs to use both clinical trial data and real world data to provide optimal patient care for the anticoagulated patient with life-threatening bleeding. Previous Article Posterior Circulation Horror Stories: How To Save the Day and Your Patient Next Article MRI In Acute Stroke: Promises and Pitfalls Print 8190 Rate this article: No rating 1 comments on article "The Role of Real World Evidence in Driving Clinical Care for Anticoagulated Patients with Life-Threatening Bleeding" Benjamin Befeler There is No info on CMEs 5/4/2023 7:34 AM Please login or register to post comments.